Rosiglitazone Production Cost Reports

The report provides a detailed analysis essential for establishing a Rosiglitazone production plant. It encompasses all critical aspects necessary for Rosiglitazone production, including the cost of Rosiglitazone production, Rosiglitazone plant cost, Rosiglitazone production costs, and the overall Rosiglitazone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Rosiglitazone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Rosiglitazone is an oral antidiabetic API used to improve insulin sensitivity in adults with type 2 diabetes mellitus, deployed as monotherapy or in combination with other agents via PPARγ activation in adipose and metabolic tissues. It is also formulated in fixed-dose combinations with metformin for broader glycaemic control in industrially manufactured tablets and is widely used as a PPARγ agonist reagent in cell-based research to induce adipogenesis and study metabolic gene networks. It is an FDA approved thiazolidinedione for type 2 diabetes that lowers glucose by enhancing cellular insulin response through PPARγ activation without stimulating pancreatic insulin secretion.

The market demand for rosiglitazone is driven by the increasing global prevalence of type 2 diabetes mellitus (T2DM), driven by ageing populations, sedentary lifestyles, and unhealthy diets, which fuels demand for effective oral antidiabetic agents. The global rise in awareness among patients and healthcare providers about the importance of glycaemic control and insulin sensitisation supports the uptake of rosiglitazone-based therapies. Availability of cost-effective generic rosiglitazone formulations and fixed-dose combination products (e.g., rosiglitazone with metformin) improves patient compliance and broadens market access. Advances in drug delivery technologies, such as extended-release formulations and potentially injectable or transdermal versions, enhance efficacy and patient adherence.

Additionally, pharmaceutical industry investments in research and development to optimise rosiglitazone formulations, explore new indications beyond diabetes, and develop biosimilars, driving competitiveness, propel the market growth. Fluctuations in demand due to clinical guidelines, safety perceptions, and availability of alternative therapies impact industrial rosiglitazone procurement. Regions with high diabetes prevalence and favourable formulary status have stronger procurement needs and thus influence the overall procurement.

Raw Material for Rosiglitazone Production

According to the Rosiglitazone production plant project report, the various raw materials for Rosiglitazone production include 4-fluorobenzaldehyde and 2,4-thiazolidinedione.

Production Process of Rosiglitazone

The extensive Rosiglitazone production cost report consists of the following major industrial production process:

1. Production via Knoevenagel condensation: The production process of rosiglitazone initiates with a key first step of Knoevenagel condensation between 4-fluorobenzaldehyde and 2,4-thiazolidinedione to form 5-(4-fluorobenzylidene) thiazolidine-2,4-dione. This condensation uses a safer, nonvolatile deep eutectic solvent as the reaction medium and proceeds efficiently within 2 hours at 80 degree Celsius. In the second step, the intermediate 2-(N-ethyl-N-(pyridin-2-yl) amino) ethanol is synthesised and then condensed with the product of the first step using dimethyl sulfoxide and potassium carbonate to obtain (Z)-5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]-methylene]-2,4-thiazolidinedione within 4 hours. The final rosiglitazone is obtained by reduction of this intermediate with methanol–magnesium.

Properties of Rosiglitazone

Rosiglitazone is a white to off-white powder with a chemical formula C18H19N3O3S and a molecular weight of 357.43 g/mol. It has a melting point in the range of 153–158 degree Celsius and is sparingly soluble in water but readily soluble in solvents like DMSO, DMF, and ethanol. It is a thiazolidinedione derivative with a pyridinylaminoethoxy-phenyl substituent, acting as a selective and potent agonist of the PPARγ receptor. It exhibits moderate lipophilicity (cLogP ~3), a pKa around 6.3–6.8, and exists as a racemic powder with rapid enantiomer interconversion.